SynthesisWorld journal of gastroenterology2025
Epidemiology of metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis and associated cardiometabolic factors in adults in China (2013-2023): A systematic review and meta-analysis.
Synthesis in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Liver CT-based composite biomarkers can identify MASH and steatosis grade in people with obesity prior to bariatric surgery: a retrospective study.BMC gastroenterology · 2026Article
- Current Trends in the Epidemiology of Obesity and the Association Between Obesity and Metabolic Liver Disease (MASLD/MASH).Diabetes, obesity & metabolism · 2026Review
- The liver-brain axis, from its function to preventive therapeutic strategies in diseases.Frontiers in endocrinology · 2026Review
- Tao-Hong-Si-Wu-Tang protects against methionine- and choline-deficient diet-induced hepatic steatosis in rats and is associated with inhibition of oxidative stress, inflammation, apoptosis, and pyroptosis.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough epidemiological data on non-alcoholic fatty liver disease in China are available, data on cardiometabolic risk factors have not been addressed under the metabolic dysfunction-associated steatotic liver disease (MASLD) consensus.
aimTo synthesize the epidemiological characteristics of MASLD/metabolic dysfunction-associated steatohepatitis (MASH), especially their associated cardiometabolic risk factors in China.
methodsWe searched EMBASE, MEDLINE, Central Cochrane, CNKI, and Wangfan for studies from January 1, 2013 to December 31, 2023. Studies involving individuals with MASLD/MASH in China that reported epidemiological outcomes were included. Meta-analysis was performed to assess the prevalence of MASLD/MASH. Exploratory outcomes included extrahepatic comorbidities and genetic variants related to MASLD.
resultsIn total, 561 studies involving 6632718 participants were included in this analysis. The prevalence of MASLD and MASH and the annual incidence of MASLD were 30.4% [95% confidence interval (CI): 29.4-31.3], 6.7% (95%CI: 2.2-13.4), and 37 cases per 1000 person-years (95%CI: 28-47), respectively. In addition, the prevalence rates of MASLD in individuals with dyslipidemia, obesity, and hypertension were 59.9% (95%CI: 52.6-67.0), 53.9% (95%CI: 47.9-59.9), and 44.3% (95%CI: 41.1-47.6), respectively. The prevalence of lean MASLD (body mass index < 24 kg/m
conclusionThis study provides a comprehensive overview of the epidemiology and disease burden of MASLD/MASH in China, providing additional evidence for optimizing MASLD/MASH management in China and a reference for the global understanding of MASLD/MASH epidemiology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.